You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Pharmacogenomics 101 for Primary Care Teams

  • Authors: Sagar Parikh, MD, FRCP; Charles Vega, MD; Michael Thase, MD
  • CME / ABIM MOC / CE Released: 9/28/2022
  • Valid for credit through: 9/28/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care physicians, psychiatrists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with psychiatric disorders.

The goal of this activity is for learners to be better able to equip primary care teams to identify patients who may benefit from pharmacogenomics (PGx) testing and select patients and incorporate testing into their practices.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Influence of genetic factors on patients’ drug response
    • Use of PGx as a decision-support tool
  • Have greater competence related to
    • Identifying patients who may benefit from PGx testing
  • Demonstrate greater confidence in their ability to
    • Apply a team-based approach when communicating with patients about PGx


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Sagar Parikh, MD, FRCP

    Professor of Psychiatry
    University of Michigan
    Ann Arbor, Michigan 

    Disclosures

    Sagar Parikh, MD, FRCP has the following relevant financial relationships: 
    Consultant or advisor for: Aifred; Janssen; Mensante; Myriad; NeonMind; Sage; Takeda
    Speaker or member of speakers bureau for: Otsuka
    Research funding from: Aifred; Janssen; Merck; Sage

  • Charles Vega, MD

    Professor of Family Medicine
    University of California
    Irvine, California

    Disclosures

    Charles Vega, MD has the following relevant financial relationships: 
    Consultant or advisor for: GlaxoSmithKline; Johnson & Johnson

  • Michael Thase, MD

    Professor of Psychiatry
    Pearlman School of Medicine
    University of Pennsylvania
    Philadelphia, Pennsylvania 

    Disclosures

    Michael Thase, MD has the following relevant financial relationships: 
    Consultant or advisor for: Acadia Pharmaceuticals; Akili; Alkermes; Allergan; Axsome; Biohaven; Bocemtium; Boehringer Ingelheim; CatalYm; Clexio; Gerson Lehrman Group; H. Lundbeck; Janssen; Jazz; Johnson & Johnson; Merck; Otsuka; Pfizer; Sage; Seelos; Sunovion; Takeda
    Research funding from: Acadia Pharmaceuticals; Allergan; AssureRx; Axsome; Biohaven; Intracellular; Johnson & Johnson; Otsuka; Takeda

Editor

  • Faisal Islam, MD, MBA

    Medical Education Director, Medscape, LLC

    Disclosures

    Faisal Islam, MD, MBA, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology. 

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-22-337-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Pharmacogenomics 101 for Primary Care Teams

Authors: Sagar Parikh, MD, FRCP; Charles Vega, MD; Michael Thase, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 9/28/2022

Valid for credit through: 9/28/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

What Is Pharmacogenomics?

Dr Parikh provides an overview of the utility of PGx in clinical practice.
Sagar Parikh, MD, FRCPC

Identifying Patients With Psychiatric Illness Who Might Benefit From Pharmacogenomics

Dr Vega provides insight into identifying patients who are most likely to benefit from PGx.
Charles Vega, MD

Individualizing Psychotropic Treatment Decisions Through Pharmacogenomics

Dr Vega discusses challenging cases involving PGx testing.
Charles Vega, MD

Best Practices in Communicating With Your Patients About Pharmacogenomics

Dr Thase explores PGx as a decision support tool and team-based approach.
Michael Thase, MD
 

Educational Impact Challenge

The goal of this activity is for learners to be better able to equip primary care teams to identify patients who may benefit from pharmacogenomics (PGx) testing and select patients and incorporate testing into their practices.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.